Fischer Medical Ventures Ltd

AGM Details

• 33rd AGM held on 29/09/2026 via video conferencing at 11:00 IST.
• NSDL facilitated AGM through VC and e-Voting.
• Cut-off date for voting eligibility: 22/09/2026.
• 61 members joined via VC; quorum met.
• Voting conducted via remote e-Voting prior to the meeting.
• Post-meeting e-Voting window of 30 minutes.

Auditors & Scrutiniser

• Auditors' Report and Secretarial Audit Report had no qualifications.
• Scrutiniser for e-voting: Mr. Nuren Lodaya.

Dividend declarations by material subsidiaries

• Time Medical Int'l Ventures (India) Pvt Ltd declared Rs 6.50 crore dividend for FY2026.
• FlynnCare Health Innovations Pvt Ltd declared Rs 10 crore dividend for FY2026.
• FMV Global Innovation Pte Limited declared interim dividend USD 1.10 million for year ended 31 March 2027.
• All three are material wholly-owned subsidiaries of Fischer Medical Ventures Ltd.

Financial performance

• Consolidated revenue FY2025-26: ₹308.58 crore.
• Consolidated EBITDA FY2025-26: ₹55.40 crore; margin 17.21%.
• Consolidated net profit FY2025-26: ₹31.07 crore; PAT margin 9.67%.
• Total assets (consolidated) ₹671 crore.
• Basic EPS ₹0.48; Diluted EPS ₹0.45.
• Market cap as at 31 Mar 2026: ₹2,644.89 crore.
• Dividend per share ₹0.05; 5% dividend proposed for FY2025-26.
• Total debt incl leases ₹10,707.53 Lakhs; Net debt ₹8,202.95 Lakhs.
• Debt to equity 0.28; Current ratio 1.62; ROE 8.07%.
• Inventory turnover 28.27; New Government Orders USD 7 Mn+.

Capital structure & liquidity

• Paid-up capital ₹65.45 crore.
• Total equity (consolidated) ₹38,514.22 Lakhs.
• Total debt incl leases ₹10,707.53 Lakhs; Net debt ₹8,202.95 Lakhs.
• Debt to equity ratio 0.28; current ratio 1.62.

Dividends & capital allocation

• Dividend per share ₹0.05; 5% of face value.
• Record date for dividend: 22 Sep 2026.
• Share capital split: Rs 10 to Rs 1 per share; record date 12 Sep 2025.
• Conversion of warrants led to equity issuance; capital structure adjusted.

Strategy & growth outlook

• Next phase: expand imaging portfolio; helium-free QUIN, MICA; DRIS-iMRI; VEGA; NEXA progress.
• AI-enabled preventive healthcare: expand FlynnCare with eHAP, MIDAS, ATLAS.
• International expansion across SEA: Philippines, Indonesia, Singapore, Malaysia.

Operations & manufacturing

• AMTZ facility scaled; CDSCO approvals for Spincare and imaging platforms.
• Launches: QUIN and MICA; DRIS-iMRI; VEGA for rapid screening.
• Quality systems and parallel regulatory pathways underpin multi-country deployments.

Governance & board

• Mr. David Yeow appointed Independent Director for five years from 3 Sept 2026.
• Board size at eight directors; six independent.
• Audit Committee comprises six Independent Directors; governance strengthened.

Subsidiaries & geography

• Material subsidiaries include TMIV (India) 100%, FlynnCare 100%, FMV Global Innovations (Singapore) 100%.
• Geography: India, Singapore, Philippines, Indonesia, Malaysia.

ESG & sustainability

• Helium-free MRI technology reduces helium dependency and operating costs.
• AMTZ facility supports energy-efficient, sustainable manufacturing.

Fischer Medical Ventures Limited — Closure of Trading Window from October 01, 2026 till 48 hours after the declaration of Un-Audited Financial Results for the quarter ended September 30, 2026.

Rights issues approved

• TMIV: 15,603 shares at ₹7,370.25 each.
• FlynnCare: 1,507 shares at ₹82,943.48 each.
• FMV Global Innovation: 53 shares at ₹48,83,552.64 each.

Parent investment in subsidiary rights issues

• TMIV investment: ₹11.50 crore for 100% stake.
• FlynnCare investment: ₹12.50 crore for 100% stake.
• FMV Global Innovation Pte Ltd investment: ₹26.00 crore for 100% stake.
• Total consideration: ₹50.00 crore; cash consideration.
• Related party, arm's length; valuation by Registered Valuer.

Rights issues by subsidiaries

• Time Medical International Ventures (India) Private Limited issued 15,603 equity shares at ₹7,370.25 each under rights issue.
• FlynnCare Health Innovations Private Limited issued 1,507 equity shares at ₹82,943.48 each under rights issue.
• FMV Global Innovation Pte. Ltd. issued 53 equity shares at ₹48,83,552.64 per share under rights issue.

Parent investment in subsidiaries

• Board approved investment in subsidiaries' rights issues.
• TMIV: Cash consideration INR 11,50,00,000 for 100% stake.
• FlynnCare: Cash consideration INR 12,50,00,000 for 100% stake.
• FMV Global Innovation Pte Ltd: Cash consideration INR 26,00,00,000 for 100% stake.

Related party confirmations

• TMIV is a wholly owned subsidiary; related party; arm's length; valuation by Registered Valuer.
• FlynnCare is a wholly owned subsidiary; related party; arm's length; valuation by Registered Valuer.
• FMV Global Innovation Pte Ltd is a wholly owned subsidiary; related party; arm's length; valuation by Registered Valuer.

Investor presentation update

• Revised investor/analyst presentation submitted under Regulation 30 for the Sept 7, 2026 call.
• Governance details listed, including Chairman & MD Ravindran Govindan; independent directors named.
• No new financial metrics disclosed in this chunk.

Event overview

• Revised investor/analyst presentation submitted for Sep 7, 2026 call.

Business and Market Update

• Radiology remains FMV's largest segment with in-house MRI platforms and broad diagnostics.
• Tamil Nadu order: Rs 9.29 crore for 65-unit imaging package.
• WFNS partnership: FMVL named industry partner in neurosurgical imaging.

International Expansion

• Indonesia market entry Oct 2024 with Trace-Test-Treat-Track TB solution.
• Philippines Bulacan MRI installation in Nov 2025; tele-radiology enabled.
• Catanduanes province-wide digital health model with PhilHealth YAKAP accreditation.

Capital and Governance

• Promoter warrants converted; ₹59.67 crore promoter capital infusion.
• Promoter stake increased to 63.08% post-investment.
• Quarterly progress updates to stock exchanges; ongoing disclosures promised.
• Vecura AI-enabled molecular research collaboration to accelerate India drug discovery.